Skip to content
Podcast 127: Why QALYs matter episode artwork

Aug 4, 2011 16 min

Podcast 127: Why QALYs matter

from Clinical Conversations Hosted by NEJM Group

This time we talk with Dr. Katia Noyes, first author on a study of the cost-effectiveness of disease-modifying drugs in multiple sclerosis. If you don’t treat MS, don’t think that the topic is irrelevant. Noyes brings the issues of cost-effectiveness and the dreaded QALY into focus for clinicians who see patients. After all, medical costs will undoubtedly become centerpieces of political debate over the next year and beyond. We’d all be better off being able to evaluate the arguments made. Noyes et al.’s article in Neurology (abstract) Physician’s First Watch coverage Peter Neumann’s book, “Using Cost-Effectiveness Analysis to Improve Health Care” (Amazon link) Gold et al.’s book, “Cost-Effectiveness in Health and Medicine” (Amazon link) The post Podcast 127: Why QALYs matter first appeared on Clinical Conversations.

Episode details come from the podcast's RSS feed.

Embed this episode

This time we talk with Dr. Katia Noyes, first author on a study of the cost-effectiveness of disease-modifying drugs in multiple sclerosis. If you don’t treat MS, don’t think that the topic is irrelevant. Noyes brings the issues of cost-effectiveness and the dreaded QALY into focus for clinicians who see patients. After all, medical costs will […]

Ready to play

Podcast 127: Why QALYs matter

0:00 16:21

Chapters

  1. 0:00 Intro
  2. 0:15 Interview
  3. 16:03 Outro

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Clinical Conversations?

This episode is 16 minutes long.

When was this Clinical Conversations episode published?

This episode was published on August 4, 2011.

Can I download this Clinical Conversations episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.